NCT04291703: A trial that was reported late by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
This trial has reported, although it was 97 days late in doing so.
Full data
| Full entry on ClinicalTrials.gov | NCT04291703 |
|---|---|
| Title | Low Dose Antithymocyte Globulin (ATG) to Delay or Prevent Progression to Stage 3 T1D |
| Results Status | Reported (late) |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Nov. 1, 2023 |
| Completion date | Dec. 17, 2024 |
| Required reporting date | Dec. 17, 2025, midnight |
| Actual reporting date | March 24, 2026 |
| Date last checked at ClinicalTrials.gov | March 26, 2026 |
| Days late | 97 |